Burning Rock Biotech Limited

    Jurisdiction
    China
    ISIN
    US12233L1070 (BNR)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. Read full profile

    Fundamentals

    Net revenue
    €61.37M
    Gross margin
    70.3%
    EBIT
    -€42.54M
    EBIT margin
    -69.3%
    Net income
    -€41.24M
    Net margin
    -67.2%

    Statement period: - (published )

    Products

    Product Revenue
    Service €290.74M 473.7%
    Product €225.08M 366.7%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 32K $142.72K -600 Sell

    Earnings Calls

    Latest earnings call: May 29, 2024 (Q1 2024)

    Add to watchlist

    Notifications